Corcept Therapeutics CFO Mokari Atabak sold 40,000 shares on July 15, 2026, in a transaction valued at $3.5 million, according to an SEC filing. The sale was executed through a cashless exercise of options at $19.26 and $23.06 per share, with all resulting shares sold at a weighted average price of $87.71. The transaction was conducted under a Rule 10b5-1 trading plan adopted on December 12, 2025, the same month the stock lost half its value in a single session before more than doubling by the sale date. Following the sale, Atabak directly holds 16,130 shares, but his total economic exposure remains substantial through nearly 180,000 derivative securities. Corcept, a specialty pharmaceutical company with a market capitalization of $9.6 billion, saw its stock recover after FDA approval of relacorilant for ovarian cancer, now sold as Lifyorli, and raised full-year revenue guidance to as much as $1.05 billion.
Corcept Therapeutics IncorporatedCFO sold shares under a pre-set plan adopted after a crash; stock later recovered on FDA approval and raised guidance, but the sale itself is neutral; the article highlights the stock's recovery and strong fundamentals.